Tolfenamic acid, a nonsteroidal anti-inflammatory drug approved for the treatment of migraine headaches, has been shown to inhibit pancreatic cancer cell growth in vitro and pancreatic and esophageal tumor growth in vivo by inducting the proteosomal degradation of Sp factors [316-320]. This evidence concerns the gene TFF2 and neoplasm of esophagus.